840 related articles for article (PubMed ID: 12676739)
1. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
2. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
3. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
4. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
5. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
Dzau VJ
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor.
Carstens J; Pedersen EB
Scand J Clin Lab Invest; 2008; 68(1):2-10. PubMed ID: 17852806
[TBL] [Abstract][Full Text] [Related]
8. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
9. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
[TBL] [Abstract][Full Text] [Related]
10. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
11. Losartan attenuates renal vasoconstriction in response to acute unilateral ureteral occlusion in pigs.
Hvistendahl JJ; Pedersen TS; Djurhuus JC; Pedersen EB; Frøkiaer J
Urol Res; 2002 Jul; 30(3):169-77. PubMed ID: 12111180
[TBL] [Abstract][Full Text] [Related]
12. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
13. Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
Starklint J; Bech JN; Nyvad O; Jensen P; Pedersen EB
Scand J Clin Lab Invest; 2006; 66(1):55-66. PubMed ID: 16464787
[TBL] [Abstract][Full Text] [Related]
14. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
15. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.
Martin FL; Chen HH; Cataliotti A; Burnett JC
Rev Cardiovasc Med; 2008; 9(1):39-45. PubMed ID: 18418308
[TBL] [Abstract][Full Text] [Related]
16. Unloading therapy by intravenous diuretic in chronic heart failure: a double-edged weapon?
De Vecchis R; Ciccarelli A; Pucciarelli A
J Cardiovasc Med (Hagerstown); 2010 Aug; 11(8):571-4. PubMed ID: 20588135
[TBL] [Abstract][Full Text] [Related]
17. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
18. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.
Gottlieb SS; Brater DC; Thomas I; Havranek E; Bourge R; Goldman S; Dyer F; Gomez M; Bennett D; Ticho B; Beckman E; Abraham WT
Circulation; 2002 Mar; 105(11):1348-53. PubMed ID: 11901047
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin-converting enzyme inhibition on renal adaptations to acute furosemide administration in conscious rats.
Bak M; Shalmi M; Petersen JS; Poulsen LB; Christensen S
J Pharmacol Exp Ther; 1993 Jul; 266(1):33-40. PubMed ID: 8392557
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
